Drug intelligence / Profile preview

CAD-2000

Development stage: Preclinical
Lead developer: Cadrenal Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CAD-2000 is an orally bioavailable small molecule inhibitor of 12-lipoxygenase (12-LOX) currently under development by Cadrenal Therapeutics. As a next-generation compound within the company's 12-LOX portfolio, it is designed to target inflammatory pathways that contribute to metabolic dysfunction. Preclinical studies have demonstrated that oral administration of CAD-2000 improves glycemic control, preserves pancreatic β-cell function, and reduces the presence of inflammatory cells and pro-inflammatory cytokines in adipose and pancreatic tissues. The drug is being positioned for the treatment of inflammatory conditions, specifically obesity and Type 2 diabetes.

Beyond the preview

Go deeper on CAD-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAD-2000.

Explore the full profile